Viking Therapeutics (VKTX) Receives a Buy from Truist Financial

In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report). The company’s shares closed yesterday at $78.01.

According to TipRanks, Lee is a 5-star analyst with an average return of 25.7% and a 48.76% success rate. Lee covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Wave Life Sciences, and Catalyst Pharma.

Viking Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $113.50.

VKTX market cap is currently $8.6B and has a P/E ratio of -83.88.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Viking Therapeutics (VKTX) Company Description:

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company’s clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.